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ABSTRACT

Introduction: Pemphigus vulgaris (PV) is a rare autoimmune disease that causes painful blistering.
Interleukin-15 (IL-15) as a member of the immunoregulatory cytokines family is associated with the
development of the chronic inflammatory or autoimmune disease. There is not much information
available in the literature on the exact role IL-15 plays in PV.
Objectives: The goal of this study was to evaluate the serum levels of IL-15 in patients with PV and
assess the association of IL-15 with anti-desmoglein antibodies and the severity of the disease.
Methods: Fifty-three individuals affected with active PV and 38 age- and gender-matched healthy
controls were participated in this study. Disease severity was assessed using Autoimmune Bullous Skin
Disorder Intensity Score (ABSIS). Serum levels of IL-15 (pg/mL) and anti-desmoglein antibodies (Dsg1, 3)
were determined.
Results: In the patient group, IL-15 serum levels were statistically higher than those in the control
group (3.71 ± 1.5 vs. 0.79 ± 1.03, P < 0.001). A positive correlation was found between serum levels
of IL-15 and ABSIS (r = 0.5, P = 0.04). We found no significant correlation between serum concentrations of IL-15 and antidesmoglein antibodies (Dsg1 or Dsg3).
Conclusions: An increase in serum level of IL-15 in patients with PV and its relationship with disease
severity suggest that this cytokine possibly contributes to the pathogenesis of the disease and targeting
IL-15 will likely provide a new insight into the treatment of this disease.
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Introduction

study. Among 53 patients, 37 cases were newly diagnosed

Pemphigus vulgaris (PV) is a rare autoimmune disorder that

therapy (5-10 mg prednisolone per day). PV was diagnosed

causes painful blisters and erosions on the skin and mucosa

based on clinical evidence, histopathologic findings, Direct

[1]. PV is caused by environmental and genetic factors that

Immune-Fluorescence examination and the detection of se-

lead to immunological impairments. Auto-antibodies against

rum autoantibodies by ELISA. Participants with any history

the desmosomal adhesion proteins of epidermal keratino-

of inflammatory/autoimmune diseases, hematologic and

cytes, desmoglein3 and/or desmoglein 1, lead to the loss of

solid malignancies, viral hepatitis, and HIV were excluded.

epidermal cell adhesion and development of erosive lesions

This study was approved by the ethical committee of our skin

[1,2]. To date, different cytokines, such as osteopontin, inter-

research center (ethical code: IR.SBMU.SRC.REC.1395.41).

leukin (IL)-4 and IL-21 have been suggested to be associated

Prior to enrollment in the study, all participants provided

with disease pathogenesis and severity [3-5]. These cytokines

written informed consent.

while 16 cases were presented with relapse during minimal

contribute to rising proinflammatory responses and production of autoantibodies through differentiation of naïve T-cells

Clinical and Laboratory Data

into effector T -ells, increased B-cell responses, and favors a

All the patients enrolled in the study had an active disease,

class switch to IgG4. Interfering with the function of them

defined as the development of at least 3 de novo blisters/

using monoclonal antibodies, such as dupilumab for IL-4/

erosions, which do not heal spontaneously within one week.

IL-4 receptor could be probably effective in treating some

The Autoimmune Bullous Skin Disorder Intensity Score

PV patients [6,7]. In contrast, regulatory cytokines, such as

(ABSIS) was used to assess the severity of the disease. The

TGF-β and IL-35-dependent mechanisms could mediate res-

ABSIS provides a maximum score of 206 (150 points for

toration of self-tolerance, which had been broken in patients

skin involvement, 11 points for oral involvement, and 45

with autoimmune diseases [8,9]. However, the role of some

points for subjective oral discomfort) [16]. The score is

less studied cytokines, such as IL-15 has remained controver-

determined by calculating the percentage of blisters in-

sial. To our best knowledge, 3 studies have assessed the serum

volvement and erosions on the skin, along with weighting

levels of IL-15 in PV patients. Two have reported increased

factors at the stage of the blistering and erosions, respec-

serum levels of IL-15 and one suggested suppressed produc-

tively. Discomfort during eating and drinking is also consid-

tion of IL-15 as compared to the healthy controls [10-12].

ered [16]._ENREF_16

IL-15 is a glycoprotein cytokine produced by multiple cell
types including monocytes, macrophages, dendritic cells, fibroblasts, and epithelial cells. It is well known that IL-15 contributes to the survival and proliferation of T-cell [13]. It also
increases the proliferation of B lymphocytes and promotes their
differentiation into the plasma cells [13,14]. Recent studies have
indicated that inhibiting IL-15 with various methods may be
the goal of appropriate treatment to reduce inflammation [14].

Cytokine Measurements
For evaluating the level of IL-15 and anti-desmogleins (Dsg),
10 ccs venous blood of each participant was collected. The
blood samples were centrifuged to gather the serums. Then,
the serums were frozen at –80°C. After gathering all the samples, levels of IL-15 were measured by an ELISA kit (Diaclone,France), according to the manufacturer’s instructions.

Objectives

Using the ELISA method (Euroimmun AG) anti-Dsg 1 and 3

IL-15 is involved in the pathogenesis of a variety of auto-

units per milliliter (RU/ml) were considered positive.

immune diseases such as Sjogren disease, Behcet disease,

antibodies were measured in patients. Values ≥ 20 of relative

systemic lupus erythematous (SLE) and rheumatoid arthritis

Statistical Analysis

(RA) [3,15]_ENREF_14. There has been little information

Findings were respectively expressed as mean ± standard de-

about the exact role of IL-15 in pemphigus pathogenesis or

viation or as number (percentage) for continuous variables

how IL-15 production relates to the severity of pemphigus.

and categorical data, respectively. Independent samples t test

In this regard, the goal of this study was to assess the serum

and non-parametric Mann–Whitney U test were applied to

levels of IL-15 in patients with PV and to find out whether

compare the means of continuous variables and chi squared

IL-15 levels were associated with severity of their disease.

test was used for categorical variables. Analysis of variance
(ANOVA test) was used for comparing means between vari-

Methods
Patients

ables. To determine if there was a linear relationship between
variables, Pearson correlation testing was performed. We
used the statistical package of SPSS version 16.0.0. (SPSS Inc.)

To evaluate the serum levels of IL-15, 53 individuals with

To analyze the data. The level of significance was considered

active PV and 38 healthy individuals were enrolled in this

as P values less than 0.05.
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Results

anti-Dsg3 (r = 0.006, P = 0.9) antibodies. Serum levels of

Patient Characteristics

to total ABSIS (r = 0.5, P = 0.04).

IL-15 were positively correlated with PV severity according

Fifty-three patients with PV (35 females and 18 males) and

In the patients group, there was no significant dif-

38 healthy individuals (24 women and 14 men) were enrolled

ference in the mean levels of serum IL-15 between men

in the study. The control group was frequency-matched to

and women or between patients with cutaneous, muco-

cases by gender and age. The mean ages of patients and

sal, or mucocutaneous forms of the disease (P = 0.9 and

control subjects were equal to 45.62 ± 12.27 and 44.21 ±

0.09, respectively). There was a significant correlation

13.15, respectively. The baseline demographics and clinical

between pemphigus severity (ABSIS score) and anti-

characteristics of the participants have been presented in Ta-

Dsg3 (r = 0.3, P = 0.01) and anti-Dsg1 levels (r = 0.6,

ble 1. The two groups were comparable in age, gender, and

P < 0.001)._ENREF_15

comorbidities (Table 1).

Conclusions

Serum Levels of IL-15
PV patients had significantly higher levels of IL-15 than con-

In this study, we have evaluated plasma levels of IL-15 in pa-

trols. The mean serum levels of IL-15 ± SD in PV patients

tients with PV in the active phase of the disease and searched

were 3.71 ± 1.5 pg/ml, while for healthy controls were 0.79

for a potential relationship between levels of IL-15 and the

± 1.03 pg/ml, which was statistically different (P < 0.001).

severity of the disease. We have found that levels of IL-15 are

Figure 1 demonstrates the IL-15 levels in these two groups.

significantly higher in patients compared to healthy controls.

In patients with PV, no significant correlations were detected

Our study group results were comparable to those previ-

between IL-15 levels and anti-Dsg1 (r = 0.06, P = 0.6) or

ously reported [10,11].

8.00

IL 15

6.00

4.00

*
*
*

2.00

0.00
PATIENT

CONTROL
PARTICIPANT

Figure 1. Serum IL-15 concentrations (pg/ml) in patients with pemphigus in comparison to healthy controls. Overall, IL-15 levels in the
pemphigus group were higher than that of the control group (P < 0.001).
IL-15 = Interleukin-15.
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Table 1. Baseline demographics and clinical characteristics of patients with pemphigus
and healthy controls.
Characteristic

PV patients (N = 53)

Healthy controls (N = 38)

P

35 (66.0% )
18 (34.0% )

24 (63.2%)
14 (36.8% )

0.70

45.62 ± 12.27
46 (21 – 72 )

44.21 ± 13.15
45.50 (25 – 73)

0.60

2.6 ±2.3

—

18 (34%)
7 (13.2%)
28 (52.8%)

—

ABSIS, Mean ± SD;
Total score a

36.88 ± 24.92

—

Anti-Dsg1 Antibody (RU/ml)
Mean ±SD

238.68 ± 47.70

—

Anti-Dsg3 Antibody (RU/ml)
Mean ±SD

729.63 ± 99.05

—

3.71 ± 1.5

0.79 ± 1.03

Gender
Female
Male
Age, Years
Mean ± SD
Median (range)
Time until diagnosis or exacerbation, month
Mean ± SD
Type of pemphigus involvement
Mucosal
Cutaneous
Mucocutaneous

IL-15 (pg/ml)
Mean ± SD

< 0.001

ABSIS = Autoimmune Bullous Skin Disorder Intensity Score; Dsg = Desmoglein; IL-15 = Interleukin-15; ; SD = standard deviation.
Values are reported as numbers (%) unless otherwise specified. aTotal score is sum of objective and subjective scores.

Approximately two decades ago, D’auria et al assessed

T-cells are survived for longer periods of time , that results in

the levels of IL-15 in the serum sample of patients affected

abnormal lymphocyte activation [14]. Furthermore IL-15 is

with three different bullous dermatoses ( 5 with bullous

also involved in the activation and proliferation of Natural

pemphigoid, 15 with PV and 15 with pemphigus erythema-

Killer cells (NKs) [17]. Stern et al have suggested a possible

tosus) [10]. They showed a higher level of IL-15 serum in

role for NKs in the pathobiology of PV and D’auria et al

all the dermatosis as compared with healthy subjects. They

have shown that the number of circulating natural killer cells

also showed a significant correlation between the number of

is significantly correlated with the concentration of IL- 15 in

lesions and IL-15 serum levels [10]._ENREF_16 Addition-

patients with pemphigus [10,18].

ally, Ameglio et al showed increased levels of interleukin 15

According to the mentioned role of IL-15 in the dif-

in the serum of 15 PV patients with active disease [11]. In

ferentiation and development of involved cells in immune

contrast, in a recently conducted study, Timoteo et al with

responses, the role of this cytokine has been studied in a

the evaluation of 20 PV patients and 20 healthy controls re-

number of autoimmune diseases. There are some reports

vealed a significantly lower serum level of IL-15 in patients

showing that the mean levels of IL-15 serum are significantly

with PV than in control group patients [12]. In their study

higher in Behcet disease, SLE and rheumatoid arthritis [19].

the study population consisted of non-active patients under

Active SLE patients had significantly higher levels of IL-15

pharmacologic therapy, then their results can be confounded

serum compared to healthy controls, while it was not directly

by potential suppressive effects of immunosuppressants on

associated with disease activity [20]. The levels of IL-15 in

IL-15 secretions.

the serum and synovial fluid of patients with rheumatoid

IL-15 is assumed to be a member of the immunoregulatory cytokines family which is primarily

arthritis, were much higher compared to the controls [21].

produced by

Interestingly, the levels of IL-15 were related to the disease

monocytes, macrophage, dendritic cells, fibroblast, and ep-

severity and serum levels of IL-15 were strongly correlated

ithelial cells.

with the levels of rheumatoid factor and anti-CCP [21].

It is believed that IL-15 overexpression is associated with

Collectively these findings indicated that IL-15 is a key

the development of chronic inflammatory disease or autoim-

cytokine in several autoimmune diseases, and raises the pos-

mune disorders. When IL-15 is overexpressed, autoreactive

sibility that targeting IL15 with various anti-IL15 approaches
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may provide a new insight for the treatment of such disor-

further clarification to establish whether inhibition of IL-15

ders [19]. For instance, in an animal model of human psoria-

action might prove valuable in the treatment of PV.

sis (xenograft mouse), the IL-15 blockade led to the psoriasis
resolution [22]. In rat models of induced arthritis, weekly
administration of small interfering RNA targeting IL-15 reduces the expression of proinflammatory mediators in the
inflamed joints, alleviates disease progression and significantly inhibits the clinical, radiologic and histologic features
of rheumatoid arthritis [19].
In the case of pemphigus, corticosteroid medications that
usually used to suppress auto-antibodies, include delayed and
serious side effects [23]. Targeting B-cell by the anti-CD20
molecule (rituximab) is currently the best available agent
for the treatment of pemphigus patients not responding to
conventional treatments [24]. This drug eliminates peripheral B-cells. B-cell depletion, may not be desirable because
B-cells are essential for antibody production, activation of
T-cells and complements. Therefore, interrupting the homing
of B-cells by blocking the IL-15 pathway might be a suitable
alternative to reduce excessive inflammation [14]. Torn et al
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